Long-term, up to 3-year follow-up of a multicentre, randomized, double-blind, placebo-controlled trial (AN004T) assessing the efficacy and tolerability of 2 dosing regimens of AllerT, a combination of contiguous overlapping peptides derived from Bet v 1, in adult subjects allergic to birch pollen.

Trial Profile

Long-term, up to 3-year follow-up of a multicentre, randomized, double-blind, placebo-controlled trial (AN004T) assessing the efficacy and tolerability of 2 dosing regimens of AllerT, a combination of contiguous overlapping peptides derived from Bet v 1, in adult subjects allergic to birch pollen.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2018

At a glance

  • Drugs Birch pollen allergy immunotherapy-Anergis (Primary)
  • Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Anergis
  • Most Recent Events

    • 05 Sep 2018 Results presented in an Anergis media release.
    • 05 Sep 2018 According to Anergis media release, the data published in 2018 August issue of the Journal of Allergy and Clinical Immunology.
    • 23 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top